Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 81, Issue 4, Pages 1369-1373Publisher
IOS PRESS
DOI: 10.3233/JAD-201506
Keywords
Alzheimer's disease; amyloid-beta 42; biomarker; cerebrospinal fluid
Categories
Funding
- Simon Spies Foundation
- Absalon Foundation
- Danish Order of Freemasons - Grand Lodge of Denmark
- Ellen Morchs Fond
Ask authors/readers for more resources
The study found a significant increase in A beta(1-42) levels in the cerebrospinal fluid over a period of twelve years, independent of changes in tau. Thus, awareness of this upward trend is crucial during diagnosis and selection of historical samples for research purposes.
Amyloid-beta 1-42 (A beta(1-42)) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of A beta(1-42) levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in A beta(1-42) from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF A beta(1-42) levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available